Matriptase-1 expression is lost in XXXX and is downregulated by @entity310 in vitro.

@entity1 @entity1569 @entity15955 @entity310 @entity272
BACKGROUND AND OBJECTIVES: Matriptase-1 participates in terminal keratinocyte (KC) differentiation. Knockdown of matriptase-1 in skin equivalent cultures leads to impaired KC differentiation and retention of nuclei in the stratum corneum. Here, we investigated the expression and regulation of matriptase-1 in psoriatic skin and in KC in vitro. @entity1 AND METHODS: Matriptase-1 expression in healthy and psoriatic skin and its regulation in skin equivalents were analyzed by Western blotting, immunofluorescence staining, qRT-PCR, and activity assays. Involvement of the nuclear factor kappa B (NFkB) signaling pathway was investigated by adenoviral overexpression of a dominant-negative form of @entity15955 . RESULTS: Matriptase-1 expression was detected in the stratum granulosum of healthy @entity1 skin and in skin equivalent cultures. Its expression and activity was strongly reduced in lesional skin of @entity1 with @entity1569 . Addition of @entity310 to skin equivalent cultures resulted in complete loss of matriptase-1 expression accompanied by disturbed KC differentiation. Mechanistically, we were able to show that @entity310 -induced downregulation of matriptase-1 was inhibited by blocking the @entity15955 /NFkB signaling pathway. CONCLUSIONS: Given that matriptase-1 participates in terminal KC differentiation, its absence in @entity272 indicates that this contributes to the barrier disturbances in this disease. Our data suggests that blocking the @entity15955 /NFkB-pathway represents a potential target for the treatment of @entity1569 .
